Mario Madoerin

Discovery of Roblitinib (FGF401) as a Reversible-Covalent Inhibitor of the Kinase Activity of Fibroblast Growth Factor Receptor 4.

W. Jahnke, P. Couttet, N. Ostermann, 2020, Journal of medicinal chemistry.